Univeristy of Nebraska-Lincoln (UNL) scientist Ana Maria Vélez is pioneering a genetic treatment to contain western corn rootworm. The research seeks to contain agricultural pests by targeting ...
Report covers Silexion Therapeutics (NASDAQ: SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the company’s ...
It was not until 2018 that the US FDA approved the first therapy developed using the technique. Since then, there’s been a steady, but slow, number of RNAi treatments coming into the market. The ROBO ...
-- Novel approach to gene knockdown uses proprietary CASi (Conditionally Activated siRNA) molecules optimized to “switch” on, activating siRNA therapeutics only in selected cells -- -- CASi platform, ...
Pharmaceutical Technology on MSN
SanegeneBio and Genentech sign $1.5bn global RNAi licensing deal
The deal provides SanegeneBio with an upfront payment of $200m.
SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic ...
LONDON--(BUSINESS WIRE)--Silexion Therapeutics (NASDAQ: SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results